Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leihua Liu

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Optics Express|December 19, 2025
Frequency-space few-photon diode effectZonghao Liu, Xinyu Shi, Leihua Liu, et al.
Breast Cancer Research and Treatment|February 27, 2003
Concurrent exposure to heat shock and H7 synergizes to trigger breast cancer cell apoptosis while sparing normal cellsWenle Xia, Lys Hardy, Leihua Liu, et al.
Sensors (Basel, Switzerland)|November 19, 2015
A Unique Self-Sensing, Self-Actuating AFM Probe at Higher EigenmodesZhichao Wu, Tong Guo, Ran Tao, et al.
Oncogene|August 11, 2005
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cellsWenle Xia, Catherine M Gerard, Leihua Liu, et al.
Cancer Research|February 7, 2007
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancersWenle Xia, Intisar Husain, Leihua Liu, et al.
Plos One|February 20, 2014
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosisWenle Xia, David Gooden, Leihua Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 10, 2006
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerWenle Xia, Sarah Bacus, Priti Hegde, et al.
Molecular Cancer Therapeutics|February 4, 2010
Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelAWenle Xia, Sarah Bacus, Intisar Husain, et al.
Breast Cancer Research : BCR|September 19, 2013
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Emanual F Petricoin, Sumin Zhao, et al.
Cancer Research|February 3, 2006
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancersWenle Xia, John Bisi, Jay Strum, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Optics Express|December 19, 2025
Frequency-space few-photon diode effectZonghao Liu, Xinyu Shi, Leihua Liu, et al.
Breast Cancer Research and Treatment|February 27, 2003
Concurrent exposure to heat shock and H7 synergizes to trigger breast cancer cell apoptosis while sparing normal cellsWenle Xia, Lys Hardy, Leihua Liu, et al.
Sensors (Basel, Switzerland)|November 19, 2015
A Unique Self-Sensing, Self-Actuating AFM Probe at Higher EigenmodesZhichao Wu, Tong Guo, Ran Tao, et al.
Oncogene|August 11, 2005
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cellsWenle Xia, Catherine M Gerard, Leihua Liu, et al.
Cancer Research|February 7, 2007
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancersWenle Xia, Intisar Husain, Leihua Liu, et al.
Plos One|February 20, 2014
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosisWenle Xia, David Gooden, Leihua Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 10, 2006
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerWenle Xia, Sarah Bacus, Priti Hegde, et al.
Molecular Cancer Therapeutics|February 4, 2010
Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelAWenle Xia, Sarah Bacus, Intisar Husain, et al.
Breast Cancer Research : BCR|September 19, 2013
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Emanual F Petricoin, Sumin Zhao, et al.
Cancer Research|February 3, 2006
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancersWenle Xia, John Bisi, Jay Strum, et al.
Pageof 2